AMPK as a therapeutic target in renal cell carcinoma

Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?

(2010) I. Ben Sahra et al.   MOLECULAR CANCER THERAPEUTICS

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma

(2009) Anil Kapoor et al.   CANCER

Role of Schlafen 2 (SLFN2) in the Generation of Interferon α-induced Growth Inhibitory Responses

(2009) Efstratios Katsoulidis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of Rac1 by Simvastatin in Endothelial Cells

(2009) Ruqin Kou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Everolimus

(2009) Michael B. Atkins et al.   NATURE REVIEWS DRUG DISCOVERY

Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma

(2008) J. Woodard et al.   CLINICAL CANCER RESEARCH

Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients

(2008) H. Boon et al.   DIABETOLOGIA

Increased activated Akt expression in renal cell carcinomas and prognosis

(2008) Martina Hager et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

AMPK and Raptor: Matching Cell Growth to Energy Supply

(2008) D. Grahame Hardie   MOLECULAR CELL

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

(2008) Dana M. Gwinn et al.   MOLECULAR CELL

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

(2008) I Ben Sahra et al.   ONCOGENE